Corporate Symposia

CORPORATE SYMPOSIA

Thursday, May 4, 2017

Room Gartensaal
16:45 - 18:15

BMS: Rethinking glioblastoma: rational application of immuno-oncology research

Chair: Michael Weller, Zurich/CH

16:45 - 16:55

Welcome & Introduction
Michael Weller, Zurich/CH

16:55 - 17:15

Glioblastoma biology and treatment challenges
Michael Weller, Zurich/CH

17:15 - 17:40

Preclinical rationale for I-O-based treatment strategies

Michael Lim, Maryland/US
17:40 - 18:05Emerging clinical research for I-O in glioblastoma
Wolfgang Wick, Heidelberg/DE
18:05 - 18:15Closing, Q&A
Michael Weller, Zurich/CH

Friday, May 5, 2017

Room Kongresssaal
12:30 - 14:00

Novocure: Gliobastoma Therapy with Tumor-Treating Fields (Optune)

Chair: Michael Weller, Zurich/CH
Co-Chair: Maciej M. Mrugala, Phoenix/US

12:35 - 12:40Welcome & Introduction
Michael Weller, Zurich/CH
Maciej M. Mrugala, Phoenix/US
12:40 - 12:55Biological effects of TTFields in glioblastoma
Patrick Roth, Zurich/CH
12:55 - 13:15The EF-14 newly diagnosed GBM study in the context of clinical trials: an overview about the current situation in glioblastoma treatment
David Reardon, Boston/US
13:15 - 13:35

Optune® in daily clinical practice – chances and challenges
US perspective
Maciej M. Mrugala, Phoenix/US

European perspective
Martin Glas, Essen/DE

13:35 - 13:50Outlook: TTFields in other indications
Giovanni Luca Cresoli, Bergamo/IT
13:50 - 14:00Q&A / Closing remarks / Take away messages
Michael Weller, Zurich/CH
18:15 - 19:45Scientific Symposium sponsored by MSD
Chair: Michael Weller, Zurich/CH
18:15-18:20

Welcome & Introduction
Michael Weller, Zurich/CH

18:20-18:40Role of MGMT testing: Role in clinical trial design and clinical practice
Wolfgang Wick, Heidelberg/DE
18:40-19:00Overview on current immunotherapy efforts in gliomas
Michael Weller, Zurich/CH
19:00-19:20How immunotherapy can be best integrated into current standards of care
David Reardon, Boston/US
19:20-19:40Q&A Panel Discussion
Faculty
19:40-19:45Closing Remarks
Michael Weller, Zurich/CH

Saturday, May 6, 2017

Room Kongresssaal
12:15 - 13:15

MagForce: Focal therapy in glioblastoma - current status, what's new?

Chair: Michael Weller, Zurich/CH

12:15 - 12:30Introduction, Current state of the art for glioma treatment
Michael Weller, Zurich/CH
12:30 - 12:45Focal Therapy in Gliomas – Latest Update
Michael A. Vogelbaum, Cleveland/US
12:45 - 13:00

New Aspects of Thermotherapy in Brain Tumors – NanoTherm Therapy

Walter Stummer, Münster/DE
13:00 - 13:15Discussion
Faculty
15:15 - 16:15Mundipharma: Neoplastic meningitis: a new look at a neglected problem

Chair: Michael Weller, Zurich/CH

15:15 - 15:20Welcome & Introduction
Michael Weller, Zurich/CH
15:20 - 15:35Evaluating patients outcome – experience of the German registry
Agnieszka Korfel, Berlin/DE
15:35 - 15:50

Defining the scope of the problem  – learnings of the the NeMeRe registry

Michael Glantz, Hershey/US
15:50 - 16:05Should intra-cerebrospinal therapy be a part of treatment in leptomeningeal metastasis from solid tumors?
Emilie Le Rhun, Lille/FR
16:05 - 16:15Discussion
Michael Weller, Zurich/CH
16:30 - 18:00Abbvie: Forging new paths in the treatment of glioblastoma

Chair: Michael Weller, Zurich/CH

16:30 - 16:35Introduction
Michael Weller, Zurich/CH
16:35 - 16:55Management of glioblastoma: standards of care and future directions
Michael Weller, Zurich/CH
16:55 - 17:15

Biological significance of EGFR in glioblastoma

Ken Adalpe, Toronto/CA
17:15 - 17:35

EGFR-targeted therapy of glioblastoma: the next 5 years
M
artin van den Bent, Rotterdam/NL

17:35 - 17:55

Panel discussion and Q&A
Faculty

17:15 - 17:35

Closing comments
Michael Weller, Zurich/CH